Methylation Levels of LINE-1 Predict Survival in Melanoma Patients
Author Information
Author(s): Sigalotti Luca, Fratta Elisabetta, Bidoli Ettore, Covre Alessia, Parisi Giulia, Colizzi Francesca, Coral Sandra, Massarut Samuele, Kirkwood John M, Maio Michele
Primary Institution: Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
Hypothesis
The study aimed to define the prognostic value of genomic DNA methylation levels in stage III cutaneous melanoma patients.
Conclusion
LINE-1 methylation is identified as a molecular marker of prognosis for cutaneous melanoma patients in stage IIIC.
Supporting Evidence
- Patients with hypomethylated CpG3 had increased overall survival.
- Median overall survival for hypomethylated CpG3 was 31.9 months compared to 11.5 months for hypermethylated.
- 5-year overall survival for hypomethylated CpG3 was 48% compared to 7% for hypermethylated.
Takeaway
This study found that the amount of certain DNA changes in melanoma patients can help predict how long they might live after treatment.
Methodology
The study measured genomic DNA methylation using bisulfite pyrosequencing at three CpG sites in short-term cultures from stage IIIC melanoma patients.
Potential Biases
Potential bias due to the use of short-term cell cultures instead of tumor tissues.
Limitations
The study was limited to a specific stage of melanoma and may not be generalizable to all melanoma patients.
Participant Demographics
{"age":{"median":54,"range":"29-83"},"gender":{"male":27,"female":15}}
Statistical Information
P-Value
0.01
Confidence Interval
95% CI: 1.21-5.69
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website